All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a healthcare professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The Lymphoma Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the Lymphoma Hub cannot guarantee the accuracy of translated content. The Lymphoma Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma Hub is an independent medical education platform, sponsored by Roche, AbbVie, BeOne, Miltenyi Biomedicine, Thermo Fisher, Nurix Therapeutics and Caribou Biosciences and supported through independent educational grants from Incyte, Bristol Myers Squibb, Pfizer and Takeda Pharmaceuticals U.S.A., Inc. Funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account to access:
Bookmark & personalize site content
Receive alerts for new content in your areas of interest
View lymphoma & CLL content recommended for you
ICML 2019 | Efficacy of novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for R/R NHL
Featured:
Michael DickinsonDuring ICML 2019 in Lugano, Switzerland, the Lymphoma Hub were pleased to speak to Michael Dickinson from Peter MacCallum Cancer Center, Melbourne, AU, about the efficacy of the novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for the treatment of relapsed/refractory non-Hodgkin lymphoma (NHL).
Michael Dickinson describes CD20-TCB as a CD20 CD3 bispecific antibody, which was tested in non-Hodgkin lymphoma, targeting CD20. Despite toxicities being observed in patients, it is still early days, with promising results for patients with a very aggressive refractory condition.
ICML 2019 | Efficacy of novel T-cell bispecific engaging antibody, CD20-TCB (RG6026), for R/R NHL
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
This content is accurate as of the date of publication and is not updated retrospectively. Please refer to the latest available evidence, guidelines, and relevant regulatory information when making clinical decisions.
Your opinion matters
When selecting the next therapy for patients with R/R MCL after BTKi progression, what is your most important consideration?